Abera Bioscience receives EU patent approval for key platform patent
Abera Bioscience AB (“Abera” or “the company”) has received the final decision to approve its patent application “Display of heterologous molecules on bacterial cells and
Abera Bioscience AB (“Abera” or “the company”) has received the final decision to approve its patent application “Display of heterologous molecules on bacterial cells and
FINANSIELL ÖVERSIKT TREDJE KVARTALET 2024 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 3 348 (0) kSEK Resultatet efter finansiella poster uppgick till
Abera Bioscience (“Abera” or “the Company”), the world’s leading biotechnology company in mucosal vaccines, announces that it is starting in vivo studies for its new
OSLO/STOCKHOLM, 28 october 2024 Researchers at Abera Bioscience are set to test whether their bacterial-based platform could strengthen intranasal vaccines being developed to protect against
Abera Bioscience AB (“Abera” or “the Company”) has been awarded a 1 million SEK grant from Vinnova to advance the development of its innovative pneumococcal
Abera Bioscience AB (“Abera”) is advancing its vaccine candidates, utilizing its proprietary Outer Membrane Vesicles (OMVs) and Protein Bodies platforms. One indication in the growing
FINANSIELL ÖVERSIKT ANDRA KVARTALET 2024 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 4 506 (44) kSEK Resultatet efter finansiella poster uppgick till
The Annual General Meeting 2024 of Abera Bioscience AB (“Abera” or the “Company”) was held on June 12, 2024 and made the following decisions: Approval
PhD Sohila Zadran is nominated as a new board member at the annual general meeting of Abera Bioscience AB (“Abera” or the “Company”). PhD Sohila
To the annual meeting of Abera Bioscience AB (“Abera” or “the Company”), Harry Råsted is nominated as a new board member. He possesses long experience
Sammanfattning av delårsrapporten FINANSIELL ÖVERSIKT FÖRSTA KVARTALET 2024 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 2 270 (1) kSEK Resultatet efter finansiella
English version can be found below All documents related to the Annual meeting 2024 can be found here > Kallelse till årsstämma i Abera Bioscience
Abera Bioscience AB (publ) meddelar idag att bolaget publicerar årsredovisningen för 2023. Årsredovisning finns tillgänglig på bolagets hemsida under “Investors” samt via bifogad PDF: Annual
Abera Bioscience AB (“Abera” or “the company”) has received a preliminary approval notice for the company’s patent application “Display of heterologous molecules on bacterial cells
Abera Bioscience AB (“Abera” or “the Company”) recruits Ann-Christin Magnusson as the Lab Manager for the newly established lab in Uppsala. Ann-Christin brings extensive experience
Abera Bioscience AB (“Abera” or “the Company”) is taking a significant step in its development and will establish a new laboratory in Uppsala, Sweden, during
Sammanfattning av bokslutskommuniké för 2023. FINANSIELL ÖVERSIKT HELÅRET 2023 – KONCERNEN Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 2 646 (1 850) kSEK Resultatet
Abera Bioscience AB:s (”Abera” eller ”Bolaget”) har gjort flera viktiga framsteg med sin vaccinplattform för mukosala vacciner och har därför beslutat att utveckla en nasal vaccinkandidat mot
Abera Bioscience (“Abera” or “the Company”) has concluded the last toxicological study with Ab-01.12 and received the final report, demonstrating that the vaccine is well-tolerated,
Abera Bioscience AB (“Abera” or “the Company”) is actively advancing its vaccine candidates, leveraging proprietary vaccine platforms centered around Outer Membrane Vesicles (OMVs) and Protein
Sammanfattning av delårsrapporten FINANSIELL ÖVERSIKT TREDJE KVARTALET 2023 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 0 (1 047) kSEK Resultatet efter finansiella
Abera Bioscience (“Abera”), a novel vaccine platform company specialized in mucosal vaccine development, is pleased to announce the receipt of a £ 1.8 million funding
Abera Bioscience AB:s (”Abera” eller ”Bolaget”) inleder samarbete med tre strategiska investerare – Gunnar Sachs och HW Investment Partners LLC ägt av Mats Wahlström och Kerry R.
Sammanfattning av delårsrapporten FINANSIELL ÖVERSIKT ANDRA KVARTALET 2023 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 44 (489) kSEK Resultatet efter finansiella poster
The board of Abera Bioscience has decided to reorganize the company in order to facilitate financing and collaborations for the various vaccine projects. Abera develops
Årsstämma 2023 i Abera Bioscience AB (”Abera” eller ”Bolaget”) hölls den 14 juni 2023. Årsstämman fattade följande beslut. Fastställande av resultat- och balansräkning Årsstämman
Abera Bioscience AB today publish the annual report for 2022 in Swedish, see below. Read it here: Abera Bioscience Årsredovisning 2022
English version can be found below All documents related to the Annual meeting 2023 can be found here > Kallelse till årsstämma i Abera Bioscience
Sammanfattning av delårsrapporten FINANSIELL ÖVERSIKT FÖRSTA KVARTALET 2023 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 1 (300) kSEK Resultatet efter finansiella poster
Abera Bioscience AB (“Abera” or the “Company”) announces that the first part of the toxicological study for the vaccine candidate against pneumococcus has been completed
Get in contact with us via the contact form or email: info@aberabio.com
Abera Bioscience is a platform and vaccine development company based on over 30 years of research in the medical, molecular and microbiological field. Abera was founded in 2012 as a spin-out from the Swedish protein production company Xbrane Bioscience.